Sun Pharma plans a ₹10,000 crore bond sale to refinance bridge debt from its Organon acquisition, aiming to lower interest ...

The country's largest drugmaker by market capitalisation closed a syndication of a near-$12 billion, 18-month bridge loan ...

Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon ...

Sun Pharmaceutical secures exclusive worldwide licensing rights to PCSK9 inhibitor lerodalcibep outside US and China. Read ...

India’s largest drugmaker by market capitalisation plans to raise around Rs 10,000 crore through domestic bonds to partly ...

Sun Pharma plans to raise 100 billion rupees via local bonds to refinance its Organon acquisition bridge loan amid shifting ...

Sun Pharma is planning to raise about Rs 10,000 crore through rupee-denominated bonds to partly refinance a bridge loan used for its Organon acquisition, according to Reuters. The drugmaker is ...

Sun Pharma lerodalcibep rights cover markets outside the US and China. Regulatory rollout and undisclosed economics now ...

- Sun Pharma borrowed $10 billion to acquire Organon OGN0.00%, a $6.2 billion women's health business, doubling its size ...

Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for pa ...